Kairos Pharma Ltd. (NYSE American: KAPA) announced it has been named a winner in the 2026 GHP Magazine Healthcare & Pharmaceutical Awards, receiving recognition as the USA leader in drug resistance development. The award underscores the company's focus on advancing cancer therapeutics designed to address treatment resistance, aiming to extend the effectiveness of existing cancer therapies through innovative approaches targeting drug resistance.
Based in Los Angeles, California, Kairos Pharma is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. ENV-105 is designed to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer, aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator.
This recognition from GHP Magazine highlights the importance of addressing drug resistance in cancer treatment, a major challenge that limits the efficacy of many standard therapies. By focusing on mechanisms like CD105, Kairos Pharma is working to develop therapies that could potentially improve outcomes for patients with cancers that have become resistant to existing treatments.
The award may enhance visibility for the company's research and development efforts, potentially attracting further interest from investors and collaborators. For more information on Kairos Pharma, visit the company's newsroom at https://ibn.fm/KAPA.
The full press release regarding the award is available at https://ibn.fm/WuBOf.
